Group One Trading
AKBA icon

Group One Trading’s Akebia Therapeutics AKBA Stock Holding History

Group One Trading’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.1K Buy
49,000
+23,800
+94% +$32.7K ﹤0.01% 5034
2025
Q4 		$40.6K Sell
25,200
-36,400
-59% -$76.2K ﹤0.01% 5770
2025
Q3 		$168K Sell
61,600
-200
-0.3% -$665 ﹤0.01% 4859
2025
Q2 		$225K Sell
61,800
-43,300
-41% -$119K ﹤0.01% 4217
2025
Q1 		$202K Buy
105,100
+37,900
+56% +$77.4K ﹤0.01% 4002
2024
Q4 		$128K Sell
67,200
-86,500
-56% -$150K ﹤0.01% 4310
2024
Q3 		$203K Sell
153,700
-3,400
-2% -$4.54K ﹤0.01% 3598
2024
Q2 		$160K Buy
157,100
+22,300
+17% +$27.6K ﹤0.01% 3578
2024
Q1 		$247K Buy
134,800
+73,000
+118% +$117K ﹤0.01% 3371
2023
Q4 		$76.6K Buy
61,800
+23,900
+63% +$24.4K ﹤0.01% 4696
2023
Q3 		$43.2K Sell
37,900
-20,500
-35% -$26.3K ﹤0.01% 5240
2023
Q2 		$53.4K Buy
58,400
+10,200
+21% +$9.85K ﹤0.01% 5222
2023
Q1 		$27K Buy
48,200
+23,100
+92% +$17.6K ﹤0.01% 5316
2022
Q4 		$14.5K Sell
25,100
-17,000
-40% -$5.33K ﹤0.01% 5818
2022
Q3 		$13K Sell
42,100
-11,900
-22% -$4.67K ﹤0.01% 6320
2022
Q2 		$19K Sell
54,000
-176,200
-77% -$73.9K ﹤0.01% 6315
2022
Q1 		$165K Buy
230,200
+207,600
+919% +$444K ﹤0.01% 5003
2021
Q4 		$51K Sell
22,600
-59,800
-73% -$163K ﹤0.01% 6319
2021
Q3 		$237K Sell
82,400
-49,000
-37% -$140K ﹤0.01% 4992
2021
Q2 		$498K Buy
131,400
+20,800
+19% +$70K ﹤0.01% 4227
2021
Q1 		$374K Buy
110,600
+106,100
+2,358% +$382K ﹤0.01% 4379
2020
Q4 		$13K Sell
4,500
-22,800
-84% -$66.6K ﹤0.01% 5686
2020
Q3 		$69K Sell
27,300
-8,800
-24% -$77.2K ﹤0.01% 4428
2020
Q2 		$490K Buy
36,100
+32,400
+876% +$335K ﹤0.01% 2649
2020
Q1 		$28K Sell
3,700
-7,400
-67% -$57.6K ﹤0.01% 4055
2019
Q4 		$70K Sell
11,100
-8,200
-42% -$39K ﹤0.01% 3840
2019
Q3 		$76K Buy
19,300
+1,700
+10% +$7.29K ﹤0.01% 3737
2019
Q2 		$85K Buy
17,600
+11,000
+167% +$62.6K ﹤0.01% 3474
2019
Q1 		$54K Sell
6,600
-29,700
-82% -$204K ﹤0.01% 3523
2018
Q4 		$201K Buy
36,300
+28,800
+384% +$225K ﹤0.01% 2685
2018
Q3 		$66K Sell
7,500
-9,400
-56% -$84.1K ﹤0.01% 3797
2018
Q2 		$169K Buy
16,900
+4,700
+39% +$47.1K ﹤0.01% 3184
2018
Q1 		$116K Buy
12,200
+100
+0.8% +$1.4K ﹤0.01% 3155
2017
Q4 		$180K Buy
12,100
+6,100
+102% +$101K ﹤0.01% 2985
2017
Q3 		$118K Sell
6,000
-33,900
-85% -$521K ﹤0.01% 3124
2017
Q2 		$573K Buy
39,900
+20,100
+102% +$255K 0.01% 1877
2017
Q1 		$182K Sell
19,800
-6,900
-26% -$67.4K ﹤0.01% 2576
2016
Q4 		$278K Sell
26,700
-33,500
-56% -$288K ﹤0.01% 2197
2016
Q3 		$545K Buy
60,200
+16,800
+39% +$143K 0.01% 1754
2016
Q2 		$325K Sell
43,400
-8,400
-16% -$73.3K ﹤0.01% 2052
2016
Q1 		$467K Buy
51,800
+45,800
+763% +$371K 0.01% 1735
2015
Q4 		$78K Sell
6,000
-44,400
-88% -$453K ﹤0.01% 3143
2015
Q3 		$487K Buy
50,400
+30,300
+151% +$278K 0.01% 1805
2015
Q2 		$207K Buy
20,100
+14,800
+279% +$126K ﹤0.01% 2495
2015
Q1 		$59K Sell
5,300
-3,900
-42% -$41.5K ﹤0.01% 3265
2014
Q4 		$107K Buy
9,200
+3,200
+53% +$45.9K ﹤0.01% 2790
2014
Q3 		$133K Buy
+6,000
New +$138K ﹤0.01% 2745

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Group One Trading's AKBA Position: Q1 2026 in Review

Group One Trading reduced its Akebia Therapeutics (AKBA) stake by 27% in Q1 2026, selling an estimated $48.6K and leaving 97,687 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4442.

Group One Trading first reported a position in AKBA in Q3 2014 and has held it in 37 quarters since. The position peaked at $637K in Q1 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Group One Trading held 97,687 shares of Akebia Therapeutics worth $136K as of Q1 2026.
  • Group One Trading sold 35,352 Akebia Therapeutics shares in Q1 2026, an estimated $48.6K.
  • Akebia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4442 holding.
  • Group One Trading first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 37 quarters since.
  • Group One Trading's Akebia Therapeutics position peaked at $637K in Q1 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.